THE PHARMACEUTICAL MANAGERS' INSTITUTE
LEARN|CONNECT|GROW

Market Round-up

V36 – 22nd February, 2019

General Market News:

- ***MSD*** has announced plans to start three late-stage studies of **Keytruda** (pembrolizumab) in combination with other drugs, including the PARP inhibitor Lynparza (olaparib), in patients with metastatic castration-resistant **prostate cancer.**
  LINK

- ***Novo Nordisk's*** soon-to-be-released **insulin pens** will connect to **Glooko's** diasend platform
  LINK

- ***Teva*** expects its generic version of ***Mylan's*** **EpiPen** to have about 25% share of the U.S. market by the end of 2019.
  LINK

- ***AstraZeneca's*** R&D arm, **MedImmune**, will be absorbed into the overall company as it restructures its R&D units into specific therapy areas.
  LINK

- ***Pfizer*** and ***Eli Lilly*** announce top-line results from Phase 3 study of **Tanezumab** in chronic low back pain
  LINK

- ***Takeda*** has teamed up with the drug discovery unit at the University of Dundee to develop potential treatments for diseases including **Alzheimer's**.
  LINK

- ***Abbott*** and ***Novo Nordisk*** have entered into a partnership to provide integrated digital solutions to people with **diabetes**
  LINK

- ***MSD's*** **Keytruda** tops $2 billion in quarterly sales
  LINK

- ***IQVIA*** have confirmed they are to create **100 new jobs** in Dublin in the areas of clinical project management, data management, drug safety and biostatistics.
  LINK

- ***Pfizer*** adjusts **Xeljanz** trial due to pulmonary embolism risk
  LINK

- ***MSD*** is to buy Seattle-based biotechnology company ***Immune Design*** for $300 million in cash.
  LINK

NCPE *Drug Updates*

No updates this week.

Biosimilars/Biologics:

- ***Eli Lilly*** hints that it may pursue "Branded Biosimilars" of its own products
  LINK

- ***Pfizer*** has received EC approval for **ZIRABEV**™ (bevacizumab), a biosimilar to Avastin®
  LINK

- Ahead of US biosimilar competition for **Humira**, the FDA is to give ***AbbVie's*** **Upadacitinib** priority review
  LINK

Drug Approvals/Filings:

- **NICE** draft guidance has recommended ***Roche's*** **Perjeta** (pertuzumab) for a new breast cancer indication, after an improved price offer from the company.
  LINK

- ***Roche's*** **entrectinib -** rival to ***Bayer's*** **Vitrakvi -** gets speedy FDA review
  LINK

- **FDA** grants Priority Review to ***Roche's*** **Polatuzumab Vedotin** on Lymphoma
  LINK

- ***Pfizer*** has received EC approval for **ZIRABEV**™ (bevacizumab), a biosimilar to Avastin®
  LINK

- Ahead of US biosimilar competition for **Humira**, the FDA is to give ***AbbVie's*** **Upadacitinib** priority review
  LINK

Brexit:

- **Biotech** in post-Brexit Britain: the future for the UK's pharma-innovation engine?
  LINK

- President of the European Commission **Jean-Claude Juncker** has said he was "not very optimistic" about Britain's chances of leaving the European Union with a deal, also warning that any failure to agree an orderly Brexit deal will be economically costly.
  LINK

- The Government has published legislation to prepare for a possible no-deal Brexit including support legislation ensuring continued **reciprocal healthcare** for Irish and UK citizens.
  LINK

Further reading:

- A new report, commissioned by **Cancer Research UK** and the **Greater Manchester Health and Social Care Partnership**, suggests that paying for cancer drugs based on how well they work in practice could help patients get new treatments faster.
  LINK

- Sales of **generic oncology drugs** are set to surge. A report has forecasted that the generic oncology drugs market could register an impressive 6% CAGR up to the year 2028.
  LINK